Neuberger Berman Group LLC Boosts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Neuberger Berman Group LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 147,194 shares of the life sciences company's stock after acquiring an additional 3,571 shares during the quarter. Neuberger Berman Group LLC owned 0.09% of Illumina worth $19,670,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ILMN. WCM Investment Management LLC raised its holdings in shares of Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Illumina by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares during the period. Geode Capital Management LLC increased its stake in Illumina by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock worth $354,933,000 after purchasing an additional 48,018 shares during the period. Norges Bank acquired a new position in shares of Illumina in the fourth quarter worth $228,714,000. Finally, Bessemer Group Inc. boosted its stake in shares of Illumina by 32,837.5% in the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after buying an additional 1,344,038 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Remove Ads

Illumina Trading Down 0.8 %

NASDAQ:ILMN traded down $0.60 during trading hours on Wednesday, hitting $73.99. 369,909 shares of the company were exchanged, compared to its average volume of 2,562,152. The company has a fifty day simple moving average of $86.63 and a 200 day simple moving average of $121.54. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $11.72 billion, a price-to-earnings ratio of -9.63, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Stephens reiterated an "overweight" rating and set a $156.00 target price on shares of Illumina in a research report on Tuesday, March 11th. HSBC downgraded shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and cut their price target for the company from $177.00 to $140.00 in a report on Friday, February 7th. Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Finally, Canaccord Genuity Group lowered their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $138.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.